Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N., Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Tsang, Garson, West, Brian L., Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam Y. J., Artis, Dean R., Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D'Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S., Lee, Richard J., Grippo, Joseph, Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., Chapman, Paul B., Flaherty, Keith T., Xu, Xiaowei, Nathanson, Katherine L., Nolop, Keith
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2010
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
https://ncbi.nlm.nih.gov/pubmed/20823850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09454
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia